Urticaria and silent parasitism by Ascaridoidea: Component-resolved diagnosis reinforces the significance of this association

Marta Víñas1*, Idoia Postigo2☯, Ester Suñén2☯, Jorge Martínez2☯

1 Allergy Service, Hospital de Terrassa, Consorci Sanitari de Terrassa, Carretera de Torrebonica, Barcelona, Spain, 2 Laboratory of Parasitology and Allergy, Research Center Lascaray, Department of Immunology, Microbiology and Parasitology, University of the Basque Country, Faculty of Pharmacy, Paseo de la Universidad, Vitoria, Spain

* These authors contributed equally to this work.

mvinas@cst.cat

Abstract

Urticaria remains a major problem in terms of aetiology, investigation, and management, and although parasitic diseases are considered potential causes, the absence of a consistent link between parasitic infections and skin allergy symptoms leads to the need for a deeper study of parameters that support this association. The objectives of this study were to analyse a possible relationship between parasitism by Ascarididae (Toxocara canis and Anisakis simplex) and the clinical expression of urticaria and to identify possible parasitic molecular markers for improving the diagnosis of unknown urticaria aetiology. The prevalence of Toxocara and Anisakis infestations was evaluated by measuring the levels of specific IgG (sIgG) and IgE (sIgE) antibodies against crude extracts and isolated components from whole larvae of Anisakis simplex (Ani s 1, Ani s 3 and Ani s 7) and Toxocara canis (TES-120, TES-70, TES-32 and TES-26) using immunologic and molecular diagnostic methods. A cross-sectional study was performed in a group of 400 individuals. The study group consisted of 95 patients diagnosed with urticaria (55 with chronic urticaria and 40 with acute urticaria). A control group consisted of 305 subjects without urticaria (182 diagnosed with respiratory allergy and 123 without allergy). Statistically significant differences were demonstrated in the seroprevalence of specific IgG and IgE antibodies between the urticaria patients and the healthy general population when isolated ascarid antigens were evaluated. The prevalence of IgG antibodies against Ani s 1, IgE antibodies against TES-120 and IgE antibodies against TES-70 were significantly different between the control individuals (healthy general population) and patients with urticaria. Moreover, the urticaria patient group demonstrated a higher seroprevalence of antibodies (sIgE and sIgG) against Anisakis simplex larva whole extract than the control group but just with statistically differences when sIgE was evaluated. The presence of IgE and/or IgG antibodies against Ani s 3 (tropomyosin) can help to discriminate between patients with and without urticaria. Both ascarids seem to be associated with urticaria, although in our region, Anisakis seems to have greater involvement than Toxocara in this relationship. Molecular diagnostics can be used to associate urticaria with parasite infestations. Tropomyosin and Ani s 1 were the most relevant markers for the diagnosis of unknown urticaria aetiology.
markers to demonstrate the association between urticaria and the most relevant Ascaridoidea parasites in our region.

Author summary

Urticaria remains a major problem in terms of aetiology, investigation, and management. It seems that some parasitic diseases could be causes of urticaria. Although there is no definitive consistent link between both entities, several studies have shown a significant positive association between parasite infections, mainly helminthic infections, and urticaria. The study of prevalence data for the most relevant Ascarididae infections in our region in different groups (healthy general population, respiratory allergy patients and patients with urticaria), through the measure of specific IgE and IgG antibodies against crude and molecular antigens of *Anisakis* and *Toxocara*, allowed us to define some antigenic markers that can be used to discriminate urticaria patients from the control individuals.

Introduction

Urticaria is a disease characterized by the development of wheals (hives), angioedema, or both. The differential diagnosis includes anaphylaxis, autoinflammatory syndromes, and hereditary angioedema. Chronic spontaneous urticaria is defined as the recurrent development of transient wheals (hives), angioedema, or both for >6 weeks due to known or unknown causes [1]. Chronic urticaria remains a major problem in terms of aetiology, investigation, and management, and it is important to identify patients in whom physical urticaria is the main cause of disability [2,3].

Although parasitic diseases are considered a potential cause of urticaria, the absence of a consistent link between parasitic infections and skin allergic symptoms in clinical investigations stands in contrast to the fact that some parasites are the most potent inducers of Th2 responses that exist in nature [4,5]. Consequently, a clear association between parasitic infection and chronic urticaria should be better established.

In more than 90% of chronic spontaneous urticaria cases seen in routine clinical practices, the search for underlying causes is usually unsuccessful [1]. Nonetheless, autoimmunity, food intolerance, and bacterial, viral, fungal, or internal parasitic infections have all been described as probable causes of urticaria development [6].

It is recommended to collect “fresh stool” samples from patients with unexplained eosinophilia and/or a relevant history of travel abroad, in order to test them for the presence of cysts, ova, or other parasitic forms. Serology is recommended and can play a fundamental role in those parasitic diseases that are exceedingly difficult to diagnose directly, such as toxocariasis or anisakiasis [7]. Epidemiological surveys have shown that human toxocariasis and ascariasis are two very common helminthiases caused by species of Ascarididae, with a worldwide distribution [8].

In Spain, the ubiquitous ascarids belonging to the genera *Toxocara* and *Anisakis* are highly prevalent [8]. Spain appears to have the highest reported incidence of anisakiasis in Europe, with approximately 8,000 cases per year where marinated anchovies are recognized as the main foodborne cause [8]. The prevalence of *Anisakis* sensitization varies widely, ranging from 22% [9] to 75% [10], depending on the region under study, which indicates that human
contact with *Anisakis* larvae is very common. In addition, Kolkhir et al. and Gracia-Bara et al. [6,11] found that *Anisakis* is one of the most common parasites detected in adult patients with chronic spontaneous urticaria.

The reported *Toxocara* prevalence in Spain reaches different values, ranging from 1 to more than 40% [12–14]. These differences are most likely associated with the diversity of the studied groups in each report. Portus et al., 1989 reported a *Toxocara* prevalence of 3.6% in Barcelona. Moreover, they found important differences between subjects with eosinophilia (14%) and a control group (1%) [15].

Factors that have been associated with an increased prevalence of toxocariasis include low socioeconomic level and poor environmental hygiene [13], which are possibly exacerbated by wet and warm climates, such as those in tropical regions [16,17]. Immigration from tropical regions to Europe is on the rise, with Spain as a frequent destination; this factor should be taken into account to evaluate possible urticaria symptoms due to *Toxocara* infections. Despite this, data on the high seroprevalence of toxocariasis among immigrants from Latin America to Western countries (primarily Europe, the United States and Canada) are very scarce [18–20].

On the other hand, the results regarding whether parasite infections have a protective or predictive role for allergy and asthma are controversial [21]. It seems that low-prevalence or occasional helminthiasis, which is typical in industrialized countries, has an allergic reactivity-stimulating role, while high-prevalence parasitic infections, which are typical in developing countries, has a suppressive role [21,22].

There are many reports that recommend including the serodagnosis of ascarids in the standard working diagnostic methodology, mainly in those patients who present with idiopathic chronic urticaria [23,24], with high environmental exposure [25] (rural areas, a high level of contact with dogs), with an atopic condition [26,27], and, in general, with a poor response to the usual treatment with antihistamines.

Since these parasitoses are silent in most cases, conducting these types of studies in a routine manner would allow a solid database based on evidence on which more efficient protocols for diagnosis could be proposed, while also highlighting the importance of establishing control programmes for these zoonoses and determining their role in the development of allergic manifestations [13,14,26].

Within this context, the aim of this study was to evaluate whether the two most common ascarids in Spain (*Toxocara* and *Anisakis*) might be involved in the development of urticaria and how the isolated antigenic/allergenic components of both genera could be associated with urticaria status. The application of component-resolved diagnosis could help define some diagnostic markers for urticaria caused by Ascaridoidea infections or exposure.

For this purpose, the seroprevalence of toxocariasis and anisakiasis in individuals with urticaria was measured through the presence of specific IgG (sIgG) and IgE (sIgE) antibodies against crude and isolated antigens/allergens using molecular diagnostic methods concretely Component-resolved diagnosis (CRD) [28] in comparison to that in individuals without urticaria, including healthy general population and atopic patients.

**Materials and methods**

**Ethics statement**

The Consorci Sanitari de Terrassa’s Clinical Research Ethics Committee approved the study called: “Urticaria and silent parasitism by Ascaridoidea” to be carried out at the Terrassa’s Hospital. All participating subjects signed an informed consent to collect a blood sample and publish the results anonymously.
Study population
A total of 2,798 adult patients (≥16 years old) who presented for the first time at the Allergy Service of Terrassa Hospital (Barcelona) during a 24-month period (from June 2009 to May 2011), were asked to participate in this study. Among them, 277 individuals who met the following inclusion criteria were enrolled.

Inclusion criteria
Case population: Adult subjects (≥16 years old) presenting with urticaria.
Control populations: Adult subjects (≥16 years old) sensitized to common pneumoallergens and presenting with allergy symptoms, such as rhinitis and/or asthma.

A group of 123 serum samples from the healthy general population (National Register of Biobank Serum Collections, code C.0002774; Instituto de Salud Carlos III, Ministry of Economy and Competitiveness/Lascaray Research Center, University of the Basque Country, Vitoria, Spain) was also included. None of the subjects presented allergy or urticaria symptoms, according to a personal history questionnaire filled in before the blood draw.

Clinical and epidemiological data
Clinical and epidemiological data on each subject were obtained using questionnaires designed for this purpose. The questionnaire covered age, sex, nationality, living conditions, health status, previous and current allergic manifestations, geophagia, and the presence of gastrointestinal and cutaneous symptoms, including chronic or acute urticaria, itching, and atopic dermatitis.

Other related questions, such as those regarding personal hygiene, drug use, weight loss, travel history during the last 5 years, and contact with animals, were also included in the questionnaire. The questionnaire was completed by the doctor who attended to the patients at the Allergy Service and urticaria was diagnosed following the EAACI/GA2LEN/EDF/WAO Guideline [1].

A written informed consent for diagnostic procedures and questionnaires was obtained from all patients. The study protocol was approved by the Clinical Investigation Ethics Committee of Terrassa Health Trust (Barcelona).

Skin prick tests
All patients underwent skin prick testing [29] with a standardized battery of the predominant aeroallergenic extracts of the area where the study was conducted: mites (Dermatophagoides pteronyssinus, Dermatophagoides farinae), moulds (Alternaria alternata, Cladosporium herbarum), dog and cat epithelia and pollens (Cupresaceae, Lolium perenne, Cynodon dactylon, Phragmites communis, Olea europaea, Plantanus acerifolia, Chenopodium album, Pinus sp., Parietaria judaica, Plantago lanceolata and Artemisia vulgaris).

Serum samples for biochemical and immunochemical analyses
A 5-mL serum aliquot was obtained from each patient for immunological and biochemical analyses. The samples were identified according to standard Spanish rules for biomedical investigations and stored at -40°C until analysis. Complete blood count, serum biochemistry tests (including the level of eosinophil cationic protein), and laboratory determination of total and specific serum IgE levels, when indicated, were performed.
**Immunological assays**

**Atopy.** Atopy was analysed using the ImmunoCAP Phadiatop (Thermo Fisher Scientific, USA) assay [30], a solid-phase immunoassay for serum specific IgE antibodies against a balanced mixture of relevant inhaled allergens. The manufacturer’s protocol was followed. Because *Salsola* allergen extract is not included in the ImmunoCAP Phadiatop panel, the specific IgE antibody against this allergenic source was measured in all subjects separately with an ImmunoCAP specific IgE assay (Thermo Fisher Scientific, USA).

**Immunanalysis using *Toxocara canis* L2 excretory-secretory (TES) whole antigens (WA)**

Quantification of the sIgG antibodies anti-*Toxocara canis* L2 excretory-secretory whole antigens (WATES). Quantification of the specific IgG antibodies against *T. canis* was performed by ELISA (EIA Toxocara IgG, TEST LINE Clin. Diag. Ltd., Czech Republic) according to the manufacturer’s instructions [31]. The products coupled to the solid phase were the excretory-secretory antigens from *T. canis* L2 larvae. The cut-off value was > 0.90 mg/ml.

Quantification of the sIgE antibodies anti-*Toxocara canis* L2 excretory-secretory whole antigens (WATES). Quantification of the specific IgE antibodies against *T. canis* was performed by FEIA (ImmunoCAP, Thermo Fisher Scientific, USA). Briefly, biotinylated WATES antigens were coupled to streptavidin-activated ImmunoCAPs according to the method of Rodrigo et al. [32]. The FEIA method was performed according to the manufacturer’s instructions. The cut-off value was 0.1 kU A/L.

**Immunanalysis using *Anisakis simplex* larvae whole antigens**

Quantification of the sIgG and sIgE antibodies anti-*Anisakis simplex* larva whole antigens. Quantification of specific IgE and IgG antibodies against *A. simplex* larva crude antigenic extract was carried out by FEIA (ImmunoCAP, Thermo Fisher Scientific, USA) [32,33]. The cut-off value for sIgE was 0.10 kU A/L according to the manufacturer’s instructions, and for sIgG, the cut-off value was 4.3 mg/ml calculated by ROC analysis since there are no reference normal values for sIgG.

**Component-resolved diagnosis**

Quantification of sIgG and sIgE against the *Anisakis simplex* isolated allergens *Ani* s 1, *Ani* s 3 and *Ani* s 7. Quantification of specific IgG and IgE antibodies against *A. simplex* recombinant allergens (*Ani* s 1 and *Ani* s 7) was performed by ELISA (Trisakis 170, Santiago de Compostela, Spain) [34,35,36]. The ELISA was performed according to the manufacturer’s instructions. The cut-off value for sIgE against *Ani* s 1 was > 0.10 kUA/L, > 0.05 kUA/L for sIgE against *Ani* s 7, and > 0.133 mg/ml for sIgG against *Ani* s 1 and *Ani* s 7.

Quantification of specific IgG and IgE antibodies against the *A. simplex* recombinant allergen *Ani* s 3 was performed by FEIA (ImmunoCAP, Thermo Fisher Scientific, USA). The cut-off value for sIgE was > 0.10 kUA/L and for sIgG was > 4.4 mg/ml.

**Determination of the levels of sIgG and sIgE against the TES-120, TES-70, TES-32 and TES-26 specific antigens for diagnosis of Toxocara.** Levels of sIgG and sIgE against TES-L2 antigenic extracts were analysed by immunoblotting (Immunoblot Kits Test Line Clinical Diagnostics Ltd., Czech Republic). For determining sIgG content, the manufacture’s indications were followed. To determine sIgE content, the protocol was modified according to the standard sIgE immunoblotting method used in our laboratories [37]. Briefly, serum samples were incubated while shaking overnight with immunoblotted TES antigens at 4°C. After washing
The assay was developed with anti-human-sIgE-HRP (1:10,000 dilution) (SouthBiotech) and 4-chloronaphthol. All immunological tests were performed blindly by the study group, with samples identified only by patient codes. The tests were developed by the same investigator at the Parasitology and Immunoallergy Laboratory of the Lascaray Research Center in Vitoria.

**Evaluation of results**
Quantitative variables (results of specific IgE and IgG content) were requalified into qualitative variables. The values of the variables that were equal to or greater than the cut-off point were considered positive and the values lower than the cut-off were considered negative. Therefore, 2 qualitative variables were always compared.

**Statistical analysis**
Qualitative variables are expressed as absolute frequencies and percentages, and quantitative variables are expressed as the mean ± standard deviation. Comparisons between qualitative variables were performed using the Pearson chi-square test and Fisher’s exact test with 2x2 tables. Statistical significance was accepted at p<0.05.

All data of interest were entered into an Excel 2003 for Windows database (Microsoft Corp., Redmond, WA, USA) by a single investigator. Statistical analysis was then performed in IBM SPSS Statistics for Windows, version 21.0 (IBM Corp., Armonk, NY, USA). Analysis of *Anisakis*-specific IgG antibodies was performed using GraphPad Prism version 7.03 for Windows. To calculate the cut-off value for the specific anti-*Anisakis* IgG value measured by FEIA ImmunoCAP, a receiver operating characteristic (ROC) curve was constructed.

**Results**
Table 1 shows the clinical diagnosis distribution in the 400 individuals included in the study (60% female, 40% male; mean age: 38.5 ± 12.5 years). A total of 23.75% of the studied population was diagnosed with urticaria (95/400). According to symptom persistence, 13.75% of the subjects (55/400) suffered from chronic urticaria, and 10% suffered from acute urticaria (40/400). A total of 58.25% of the patients included in the study (233/400) were diagnosed with allergy, 12.75% (51/400) suffered from allergy and urticaria, and 45.50% (182/400) suffered from allergy without urticaria. One hundred twenty-three subjects (30.75%) were considered healthy members of the general population. The individuals belonging to this group had no symptoms of allergy or urticaria, and 32% of them were atopic coinciding with the reported prevalence in the Spanish population [38].

Reference normal values for the specific anti- *Anisakis* IgG level measured by FEIA ImmunoCAP was not previously established. Therefore, in order to establish a cut-off value that would allow the calculation of the seroprevalence of this antibody class in the study population, the distribution of this value was analysed in all three groups of the study: healthy general population, patients with urticaria, and patients without urticaria.

**Table 1. Clinical group distribution of the total sample population (n = 400).**

| No urticaria | Chronic urticaria | Acute urticaria |
|--------------|-------------------|-----------------|
| N            | %                 | N              | %           | N           | %           |
| Allergic subjects | 182       | 45.50           | 23           | 5.75        | 28          | 7.00        |
| Non allergic subjects | 123      | 30.75           | 32           | 8.00        | 12          | 3.00        |
| TOTAL        | 305      | 76.25           | 55           | 13.75       | 40          | 10.00       |

https://doi.org/10.1371/journal.pntd.0008177.t001
Fig 1A shows a box-and-whisker plot of the distribution of specific anti-*Anisakis* IgG values in these three groups. The mean values (mg/ml) and their corresponding standard deviations were $3.32 \pm 1.96$ in the healthy general population, $5.10 \pm 10.20$ in patients with urticaria, and $3.22 \pm 2.30$ in patients without urticaria. Statistically significant differences were found.
between the urticaria patient group and the control groups: subjects without urticaria (p = 0.008) and the healthy general population (p = 0.039).

The optimal cut-off point for specific IgG against *Anisakis* whole larval antigen was obtained by ROC analysis (area under the curve: 0.804; standard error: 0.032; 99% confidence interval: 0.721 to 0.886; p<0.001) (Fig 1B). The mean value plus 0.5 SD (4.3 mg/ml) was chosen as the cut-off value (sensitivity, 60%; specificity, 88%).

Table 2 shows the seroprevalence (sIgE and sIgG) of *Toxocara* and *Anisakis* sensitization in the studied population. The analysis was conducted against the *Anisakis* and *Toxocara* larva whole antigens as well as against the isolated antigenic components Ani s1, Ani s 3 and Ani s 7 and TES-120, TES-70, TES-32 and TES-26 (component-resolved diagnosis [39,40]).

The seroprevalence of ascariid sensitization (positive results for specific IgG and/or IgE antibodies against *Anisakis* and/or *Toxocara* antigens) was 22.70% in the healthy general population, 39% in patients suffering from allergy without urticaria and 53.60% in patients with urticaria. The highest seroprevalence was observed in patients with acute urticaria (60%).

Among the urticaria patients, the highest prevalence was demonstrated for IgG and IgE antibodies against *Anisakis* whole extract. When the analysis using the isolated antigens from both ascarids was performed, the specific IgG antibodies followed by the specific IgE antibodies against Ani s 3 demonstrated the highest prevalence among urticaria patients (25.20 and 12.60%, respectively). The seroprevalence of both antibodies in the healthy general population was very low (0.50 and 0.25%, respectively) and slightly higher in the allergic control group (8.58 and 2.14%, respectively).

These data suggests that *Anisakis* and/or *Toxocara* whole or isolated antigens could be used as markers in the diagnosis of urticaria caused by Ascarideidae infections/exposure. With this

| Table 2. Seroprevalence (%) of specific IgG and IgE antibodies against *Toxocara* and *Anisakis* whole larva extract (WE) and isolated antigens in the groups included in the study. |
|---------------------------------|--------|-----------------|-----------------|-----------------|-----------------|
|                                | Healthy | Allergic | Total (n = 95) | Chronic (n = 55) | Acute (n = 40) |
| Anisakis (WE)                  |         |          |                |                  |                |
| IgE                            | 4.00    | 14.80    | 33.70          | 30.90            | 35.70          |
| IgG                            | 13.00   | 17.00    | 28.40          | 32.70            | 22.50          |
| Toxocara (WE)                  |         |          |                |                  |                |
| IgE                            | 6.50    | 7.10     | 11.60          | 10.90            | 12.50          |
| IgG                            | 3.30    | 5.50     | 5.30           | 3.60             | 7.40           |
| Ani s 1                        |         |          |                |                  |                |
| IgE                            | 1.60    | 4.40     | 7.40           | 7.30             | 7.50           |
| IgG                            | 3.20    | 9.90     | 11.60          | 12.70            | 10.00          |
| Ani s 3                        |         |          |                |                  |                |
| IgE                            | 0.25    | 2.14     | 12.60          | 7.60             | 5.00           |
| IgG                            | 0.50    | 8.58     | 25.20          | 14.70            | 10.20          |
| Ani s 7                        |         |          |                |                  |                |
| IgE                            | 4.30    | 8.50     | 10.50          | 5.40             | 17.50          |
| IgG                            | 1.30    | 7.30     | 6.30           | 3.60             | 10.00          |
| TES-120                        |         |          |                |                  |                |
| IgE                            | 1.60    | 2.20     | 4.00           | 3.60             | 5.00           |
| IgG                            | 0.80    | 3.30     | 2.00           | 1.80             | 2.50           |
| TES-70                         |         |          |                |                  |                |
| IgE                            | 0.40    | 1.10     | 4.10           | 3.60             | 5.00           |
| IgG                            | 0       | 1.10     | 0              | 0                | 0              |
| TES-32                         |         |          |                |                  |                |
| IgE                            | 0.80    | 0.50     | 1.00           | 0                | 2.50           |
| IgG                            | 0       | 2.20     | 1.00           | 0                | 2.50           |
| TES-26                         |         |          |                |                  |                |
| IgE                            | 0.80    | 0.50     | 1.00           | 0                | 2.50           |
| IgG                            | 0.80    | 2.20     | 1.00           | 0                | 2.50           |
| sIgE and/or sIgG against Ascaride antigens | 22.70  | 39.00   | 53.60          | 49.00            | 60.00          |

https://doi.org/10.1371/journal.pntd.0008177.t002
result in mind, a statistical analysis (Pearson chi-square and Fisher exact test) was performed, and P values were obtained among the different groups included in the study (Table 3).

When both antibody isotypes (IgG and/or IgE) against the whole or isolated larval antigen from the ascarids *Toxocara* and *Anisakis* were evaluated, statistically significant differences were demonstrated between the healthy general population controls and the subjects suffering from urticaria (p ≤ 0.001). No statistically significant differences were demonstrated between allergic patients without urticaria (control group) and the individuals with urticaria. Nonetheless, differences between allergic patients without urticaria and patients with acute urticaria were significant (p = 0.021).

When each antibody isotype was analysed regarding the antigenic source (whole larval antigens or isolated antigens), specific IgE antibodies against *Anisakis* larval whole extract were able to discriminate urticaria patients (chronic and acute) from the subjects without urticaria (the healthy general population and allergic patients without urticaria). Moreover, specific IgG antibodies against *Anisakis* larval whole extract were able to discriminate patients with chronic urticaria from the healthy general population (p = 0.003). On the other hand, none of the antibody isotypes against *Toxocara* larval whole antigens were able to discriminate between the controls and the urticaria (chronic or acute) patients.

Although statistically significant differences in the seroprevalence of specific IgE and IgG antibodies against *Anisakis* 1 between urticaria patients and the healthy general population were demonstrated, only the specific IgG antibody level was able to discriminate these groups (p = 0.028). No statistically significant differences were demonstrated between the prevalence of both antibodies in urticaria patients and in the allergic patient controls.

### Table 3. Comparative analysis of the specific IgG and IgE seroprevalences among the different study groups. Results are shown as P values.

|                      | Urticaria vs Healthy | Urticaria vs Allergy without urticaria | Chronic urticaria vs Healthy | Chronic urticaria vs Allergy without urticaria | Acute urticaria vs Healthy | Acute urticaria vs Allergy without urticaria |
|----------------------|----------------------|----------------------------------------|-----------------------------|-----------------------------------------------|---------------------------|---------------------------------------------|
| *Anisakis* (WE)      |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.000***             | 0.001***                               | 0.000***                    | 0.010**                                       | 0.000***                  | 0.003*                                      |
| IgG                  | 0.006**              | 0.050                                  | 0.003***                    | 0.021**                                       | 0.204                     | 0.495                                       |
| *Toxocara* (WE)      |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.229                | 0.261                                  | 0.369                       | 0.397                                         | 0.310                     | 0.332                                       |
| IgG                  | 0.414                | 0.494                                  | 1.000                       | 0.738                                         | 0.364                     | 0.708                                       |
| *Anisakis* 1         |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.043*               | 0.401                                  | 0.074                       | 0.481                                         | 0.095                     | 0.422                                       |
| IgG                  | 0.028*               | 0.682                                  | 0.037*                      | 0.616                                         | 0.104                     | 1.000                                       |
| *Anisakis* 3         |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.000***             | 0.000***                               | 0.018**                     | 0.005**                                       | 0.308                     | 0.208                                       |
| IgG                  | 0.000***             | 0.009**                               | 0.025*                      | 0.551                                         | 0.000***                  | 0.139                                       |
| *Anisakis* 7         |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.689                | 0.800                                  | 1.000                       | 0.740                                         | 0.239                     | 0.224                                       |
| IgG                  | 0.385                | 1.000                                  | 0.149                       | 0.475                                         | 0.669                     | 0.727                                       |
| TES-120              |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.023*               | 0.143                                  | 0.058                       | 0.392                                         | 0.013**                   | 0.058                                       |
| IgG                  | 0.045*               | 0.379                                  | 0.058                       | 0.702                                         | 0.046*                    | 0.392                                       |
| TES-70               |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.015**              | 0.049                                  | 0.094                       | 0.231                                         | 0.014**                   | 0.042*                                      |
| IgG                  | 0.189                | 1.000                                  | 0.309                       | 0.329                                         | 0.245                     | 0.551                                       |
| TES-32               |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.436                | 1.000                                  | N                          | 1.000                                         | 0.245                     | 0.451                                       |
| IgG                  | 0.170                | 0.498                                  | 0.524                       | 1.000                                         | 0.245                     | 0.158                                       |
| TES-26               |                      |                                        |                             |                                               |                           |                                             |
| IgE                  | 0.189                | 0.609                                  | N                          | 1.000                                         | 0.059                     | 0.150                                       |
| IgG                  | 0.170                | 0.498                                  | 0.524                       | 1.000                                         | 0.046*                    | 0.158                                       |
| sIgE and/or sIgG against Ascaride antigens | ≤0.001*** | 0.397 | ≤0.001*** | 0.212 | ≤0.001*** | 0.021* |

*** indicates p ≤ 0.001  
** indicates p = 0.002–0.020 and  
* indicates p = 0.020–0.05
Furthermore, both IgE and IgG antibodies against Ani s 3 were able to discriminate the chronic and acute urticaria patients from the healthy general population and from the allergic patient controls (p < 0.001). These results, together with the seroprevalence data, make Ani s 3 a candidate diagnostic marker of urticaria of unknown origin. In the case of Ani s 7, seroprevalence data for specific IgG or specific IgE did not reveal significant differences. Neither IgG nor IgE antibodies were able to discriminate between the studied groups. Among the *Toxocara* isolated antigens explored as urticaria markers, TES-70 and TES-120 were able to discriminate between acute urticaria patients and the healthy general population via specific IgE antibody levels (p = 0.014 and p = 0.013, respectively).

**Discussion**

Several authors agree that parasite infections are relatively common in patients with urticaria, but a causal link is difficult to detect. Such infections should only be regarded as the underlying cause of urticaria when treatment with anti-parasitic drugs leads both to the eradication of the parasites and the remission of urticaria.

Although routine screening for parasitic infections in patients with urticaria is not recommended, some authors [6,41] suggest that a parasitological workup may be warranted, depending on patient’s characteristics, such associated symptoms, dietary habits, country of origin and travel history.

In Europe, mainly in southern countries, anisakiasis [8] and toxocariasis [13] are the two most prevalent parasitic diseases caused by Ascaridoidea species in adults [14,15,26]. Both species are difficult to identify by direct parasitological methods. Therefore, indirect immunologic diagnosis is currently the most common strategy to determine the aetiology. In many cases, the epidemiological study of toxocariasis is limited by several factors that inhibit the assessment of the public health relevance of this parasitic infection [40].

However, to date, serological assays using *Toxocara* ES-L2 antigens or their recombinant components are the main tool for the diagnosis of toxocariasis [42]. Studies on the seroprevalence of toxocariasis in Spain have reported heterogeneous results (from 1 to >40%) depending on region, socioeconomic status, rural or urban environment, and pet ownership, among other factors. Spain-neighbouring countries show similar toxocariasis results [43,44], but in urban areas, the prevalence does not usually exceed 3%. In 2011, Turrientes et al. [44], demonstrated that the prevalence of toxocariasis in immigrants arriving in Spain was as high as 5%. They suggested that these subjects may have been infected in their countries of origin, mostly in Latin America, where prevalence rates are usually higher than those in Spain [45–47].

In the present study, the seroprevalence of IgG antibodies against *Toxocara* L2-ES whole extract was 3% in the healthy general population and 5.50% in allergic subjects without urticaria. When specific IgE antibodies were measured, the prevalence in the control and allergic groups was 6.50% and 7.10%, respectively. No statistically significant differences were found between these groups regardless of the isotype of immunoglobulin measured. These results agree with the data obtained by other authors in studies performed in similar populations and in the same country (Spain) [14,15,44]. Thus, in Barcelona, the same region where our study was carried out, Portús and colleagues [15] found a seroprevalence of 3.60%, with values of 14% in individuals with eosinophilia and 1% in controls.

Undoubtedly, the seroprevalence data measured by specific IgE and by specific IgG antibodies are more appropriate and more reflective of the real-world prevalence than data for a single parameter. In the literature, the prevalence of these parasitic infections, have been reported mainly through the use of only one parameter, i.e., specific IgG antibodies against toxocariasis or specific IgE antibodies against anisakiasis [43,48,49].
Both IgE and IgG antibodies play important roles not only as key parameters in immunological diagnoses but also as factors in several aspects of immunity, including protective strategies [48], and in assessing the clinical status of these parasitoses [43,49,50].

About *Toxocara*, the evaluation of both specific antibodies isotypes to ES-L2 whole antigens, did not show statistically significant differences among the studied groups, demonstrating similar toxocariasis low prevalence in all groups.

Unlike *Toxocara*, the seroprevalence of anisakiasis in Spain is quite high because is one of the European countries with the highest levels of fish consumption [49,51–55]. In the general asymptomatic population, the prevalence of sensitization to *Anisakis* antigens ranges from 0.40 to 27.40% [49]. Among occupationally exposed workers, such as fishermen, fishmongers, and workers in fish-processing industries, the presence of specific IgE antibodies against *Anisakis* larval whole extracts is documented in the range from 11.70% to 50% and between 50% to 100% when the allergy is exclusively associated to fish or seafood [49].

The results obtained in this work showed a 4% seroprevalence value for specific IgE antibodies in the healthy general population and 15% in allergic subjects without urticaria. This last group included patients with respiratory allergies, with mites the main cause of sensitization (95%). Lin et al. (2014) [55] and Caballero et al. (2012) [56] also studied the seroprevalence of specific IgE against *Anisakis* in atopic subjects and found very similar results to those reported herein (16% and 18%, respectively) [55,56]. In Italy, Qualizza et al. (2011) [57] found a low seroprevalence anisakiasis in allergic patients, with values very similar to those found in the present study in patients with urticaria. Frezzolini et al. (2010) [58] also found a similar distribution of *Anisakis* seroprevalence according to specific IgE measurements in atopic patients and in patients with chronic urticaria.

In the present study, the most significant differences in IgE antibodies against *Anisakis* larval whole extracts were observed between the healthy general population (4%) and patients with urticaria (33.70%). The group of allergic patients also showed significant differences from the subjects with urticaria (p = 0.001).

The use of specific IgG antibodies to assess the anisakiasis seroprevalence and its possible association with other diseases, such as urticaria [50], Crohn’s disease, gastrointestinal cancer, and others [59], has been reported in very few studies, and reference values for specific IgG antibodies against *Anisakis* antigens had not yet been defined. In our study, the establishment of normal values of specific IgG to *Anisakis* allowed to discriminate between individuals without urticaria and patients with urticaria, with special mention to the patients with the chronic urticaria. However, differences among all groups were clearly significant when the specific IgE antibodies against *Anisakis* larval whole extract were measured.

Nevertheless, the overall seropositivity, including both immunoglobulin isotypes against both ascarid whole antigens, was clearly higher in all studied groups and statistical significant differences were found between the healthy general population and patients with chronic or acute urticaria.

In recent decades, several isolated components from parasitic sources have emerged for diagnostic use. Antigens/allergens with diagnostic and prognostic value have been identified both in *Anisakis* and in *Toxocara* [48,50,60].

Several authors report that *Anisakis* components are used mainly in the molecular diagnosis of the allergy to *Anisakis*, and *Toxocara* components have been used mainly as tools for toxocariasis seroprevalence studies [48,50,60]. Few studies have investigated the diagnostic value of these components in urticaria, a condition in which these parasites could be involved [48–50,60–63]. In the present study, the Ani s 1, Ani s 3, TES-120 and TES-70 components were able to discriminate the healthy general population from urticaria patients.
In these cases, specific IgG against Ani s 1, specific IgE against TES-120 and specific IgE against TES-70 were useful and effective tools to discriminate the healthy general population from patients with urticaria.

Data on anti-Ani s 1 specific IgE from the literature are restricted to mainly healthy subjects or allergic patients, and the prevalence shown in these studies is similar to that obtained in the present investigation [55,64]. Martínez Aranguren et al. (2014) studied the antibody responses against Ani s 1 and tropomyosin and suggested that the use of recombinant versions makes it possible to distinguish between patients allergic to *A. simplex* and patients with acute urticaria who are merely sensitized to *A. simplex* [63].

The results obtained in this report, demonstrated that *Anisakis* tropomyosin was revealed as a very potent discriminative urticaria marker. Both specific IgE and specific IgG antibodies against this component were able to discriminate groups of individuals without urticaria from patients with urticaria. Moreover, the specific anti-tropomyosin IgG antibodies were also able to discriminate between the healthy population and patients with chronic or acute urticaria while specific anti-Ani s 3 IgE was able to discriminate the healthy population and allergic population from chronic urticaria patients. These results indicate that tropomyosin could be an interesting marker of urticaria associated with ascarid infections in our region.

If we accept that tropomyosin-specific IgE but not IgG antibodies play an important role in the sensitization of allergic patients, the use of both parameters could be interesting to differentiate sensitization from actual parasitic infection.

The results obtained in this work using diagnosis by components based on the Ani s 1, TES-120 and TES-70 antigens, strongly suggest that the molecular diagnosis is a useful tool for discriminating the healthy population from urticaria patients in our region.

Immunological cross reactions among different ascarids and among ascarids and mites or crustaceans have been demonstrated by several authors [65–69]. On the other hand, it has been shown that most detectable specific IgE is due to previous subclinical parasitic episodes with *A. simplex* in subjects exposed due to fish-eating habits [50,70]. Additionally, immunodiagnosis for toxocariasis reveals cross-reactivity with other nematode infections, and the positive results indicating this infection should be evaluated very carefully, especially in individuals from regions where polyparasitism is endemic or where the incidence of different parasitic nematode species in the same area is high [19]. Immunological diagnostic techniques for toxocariasis and anisakiasis are often based on the use of whole larval extracts, and the cross-reactivity phenomenon is particularly evident under these conditions. Limitations of results when whole antigens are used must be taken into account.

In our area, polyparasitism by different nematodes or the incidence of nematodes other than *Toxocara* or *Anisakis* is highly irrelevant. Therefore, only the cross-reactive antigens/allergens shared not only with other helminths but also with mites or crustaceans should be taken into account when establishing the relationship between parasitism by ascarids and urticaria. In recent years, with the use of isolated components, the concept of cross-reactivity has been reviewed, and the concept of species-specific components and cross-reactive antigens/allergens is becoming more accurate and much better delimited [51,71,72].

Investigations of Spanish and Italian patients allergic to *Anisakis* demonstrated that Ani s 1 is the immunodominant specific allergen, and the quantification of IgE specific to Ani s 1 is able to discriminate between asymptomatic and allergic patients [51,63]. Several authors have also demonstrated that some lectins, such as TES-32, are immunodominant components for diagnostic purposes [73,74]. Yamasaki and colleagues reported an increase in specificity when they used the recombinant antigen in comparison with larval crude extract. They found a decreasing percentage of cross-reactivity from 55% to 3% when the recombinant antigen was used [75].
Although cross-reactivity can be a limitation to establish the association between the studied ascarids and urticaria, mainly when larval crude extracts are used, the differences in prevalence among the urticaria patients and the reference groups found in this study are relevant enough to alleviate this limitation. This point is even more evident if we take into account the Anisakis results using mainly specific immunodominant components through IgE quantification.

Surprisingly, in our country, the panallergen tropomyosin is the component that is most significant for studying the association between ascarids, represented mainly by Anisakis and urticaria. Cross-reactions with mite allergens or shellfish allergens could also be a limitation to explain this association. The results obtained in this work show that the prevalence of tropomyosin for the allergy patients was significant lower than the obtained for the urticaria group. The differences were very significant and more so if we consider that 40% of the allergic patients were sensitized to house dust mites. A similar concept could be applied to the limitations due to shellfish allergy. Nwaru and colleagues reported a very low prevalence of shellfish allergy in Europe, with values from 0.06% and 0.10% [76].

Although both Toxocara and Anisakis seem to be involved in the association between parasitism and urticaria, in our region, the genus Anisakis appears to be the most important member of this taxonomic group regarding this association. The prevalence of anisakiasis was higher than that of toxocariasis, as was expected, as dietary habits determine the high prevalence of anisakiasis in this population.

Despite the apparent limitations to establish the ascarid-urticaria association due to mite and shellfish sensitization or other helminth infections in our region, the results obtained in this work, where helminth poly-parasitism is very scarce, strongly suggest that specific IgE and IgG antibodies against Anisakis larva crude extract, Ani s 1 and tropomyosin could be considered markers for parasite-caused urticaria. The low prevalence of Toxocara found in this study and its significance regarding the healthy general population and urticaria patients make this species a smaller factor, but it should not be excluded as a possible cause of urticaria.

The use of different antibodies isotypes and the component resolved diagnosis concept are useful to establish the association between parasite immunologic results and patients with different clinic status as allergy, acute urticaria and chronic urticaria.

Supporting information
S1 Checklist. STROBE checklist.
(DOCX)

Author Contributions
Conceptualization: Marta Viñas, Jorge Martinez.
Data curation: Marta Viñas, Idoia Postigo, Ester Suñén, Jorge Martinez.
Formal analysis: Jorge Martínez.
Funding acquisition: Jorge Martínez.
Investigation: Marta Viñas, Idoia Postigo, Jorge Martinez.
Methodology: Marta Viñas, Idoia Postigo, Jorge Martínez.
Project administration: Jorge Martínez.
Resources: Idoia Postigo, Jorge Martinez.
Software: Marta Viñas.
Supervision: Idoia Postigo, Ester Suñeñ, Jorge Martínez.
Validation: Idoia Postigo, Ester Suñeñ.
Visualization: Ester Suñeñ.
Writing – original draft: Marta Viñas, Jorge Martínez.
Writing – review & editing: Marta Viñas, Idoia Postigo, Jorge Martínez.

References
1. Zuberbier T, Aberer W, Asero R, Bindslev-Jensen C, Brzoza Z, Canonica GW et al. The EAACI/G A2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. Allergy 2014; 69: 868–887
2. Greaves M. Chronic urticaria J Allergy Clin Immunol 2000; 105:664–72. https://doi.org/10.1067/mai.2000.105706
3. Vestergaard C, Deleuran M. Chronic spontaneous urticaria: latest developments in aetiology, diagnosis and therapy. Ther Adv Chronic Dis. 2015; 6:304–313. https://doi.org/10.1177/2040622315603951
4. Bakiri AH, Mingomataj EC. Parasites Induced Skin Allergy: A Strategic Manipulation of the Host Immunity. J Clin Med Res. 2010 Dec; 2(6):247–255. https://doi.org/10.4021/jocmr456w PMID: 22043257
5. Bakiri AH, Mingomataj EC. Urticaria as Symptom of Parasite Migration Through the Biological Barriers. The Open Allergy Journal. 2011; 4:1–7.
6. Kolikhir P, Balakirski G, Merk HF, Olisova O, Maurer M. Chronic spontaneous urticaria and internal parasites–a systematic review. Allergy. 2016; 71:306–322. https://doi.org/10.1111/all.12818 PMID: 26648083
7. Powell RJ, Du Toit GL, Siddique N, Leech SC, Dixon TA, Clark AT, Mirakian R, Walker SM, Huber PA, Nasser SM. BSACI guidelines for the management of chronic urticaria and angio-oedema. Clin Exp Allergy; 2007; 37(5):631–650. https://doi.org/10.1111/j.1398-9995.1997.tb02603.x PMID: 9201371
8. Del Pozo MD, Audicana M, Díez JM, Muñoz D, Ansótegui IJ, Fernández E, et al. Anisakis simplex, a relevant etiologic factor in acute urticaria. Allergy. 1997; 52(5):576–579. https://doi.org/10.1111/j.1398-9995.1997.tb02603.x PMID: 9201371
9. Magnaval JF, Glickman LT, Dorchies P, Morassin B. Highlights of human toxocariasis. Korean J Parasitol. 2001; 39:1–11. https://doi.org/10.3347/kjpa.2001.39.1.1 PMID: 11301585
10. Cilla G, Pérez-Trallero E, Gutiérrez C, Part C, Gomariz M. Seroprevalence of Toxocara infection in middle-class and disadvantaged children in northern Spain. Eur J Epidemiol 1996; 12(5):541–543. https://doi.org/10.1007/bf00144010 PMID: 8905319
11. Fenoy S, Cuellar C, Guillen JL. Seroprevalence of toxocariasis in children and adults in Madrid and Tenerife, Spain. J Helminthol 1996; 70(2):109–113. https://doi.org/10.1017/s0022149x00015248 PMID: 8960205
12. Portús M, Riera C, Prats G. A serological survey of toxocariasis in patients and healthy donors in Barcelona (Spain). Eur J Epidemiol. 1989; 5:224–227. https://doi.org/10.1007/bf00156835 PMID: 2767231
13. Magnaval JF, Michault A, Calon N, Charlet JP. Epidemiology of human toxocariasis in La Réunion. Trans R Soc Trop Med Hyg. 1994 Sep-Oct; 88(5):531–3. https://doi.org/10.1016/0033-9203(94)90148-1 PMID: 7992328
17. Thompson DE, Bundy DA, Cooper ES, Schantz PM. Epidemiological characteristics of Toxocara canis zoonotic infection of children in a Caribbean community. Bull World Health Organ. 1986; 64:283–290. PMID: 3488844

18. Macpherson CN. Human behaviour and the epidemiology of parasitic zoonoses. Int J Parasitol. 2005; 35(11–12):1319–31. https://doi.org/10.1016/j.ijpara.2005.06.004 PMID: 16102769

19. Turrientes MC, Pérez de Ayala A, Norman F, Navarro M, Pérez-Molina JA, Rodríguez-Ferrer Met al. Visceral Larva Migrants in Immigrants from Latin America. Emerg Infect Dis. 2011; 17:1263–1265. https://doi.org/10.3201/eid1707.101204 PMID: 21762582

20. Herrador Z, Fernandez-Martínez A, Benito A, López-Vélez R. Clinical Cysticercosis epidemiology in Spain based don the hospital discharge database: What’s new?. PLoS Negl Trop Dis. 2018; 12(4): e0006316. https://doi.org/10.1371/journal.pntd.0006316 PMID: 29621234

21. Weiss ST: Parasites and asthma/allergy: what is the relationship? J Allergy Clin Immunol 2000; 105:205–210. https://doi.org/10.1016/s0091-6749(00)90067-8 PMID: 10669838

22. Hagel I, Lynch NR, DiPrisco MC, Lopez RI, Garcia NM. Allergic reactivity of children of differen t socio-economic levels in tropical populations. Int Arch Allergy Immunol 1993; 101(2):209–214. https://doi.org/10.1159/000236521 PMID: 8508056

23. Demirci M, Yildirim M, Aridogan BC, Baysal V, Korkmaz M. Tissue parasites in patients with chronic urti- caria. J Dermatol. 2003; 30(11):777–81. https://doi.org/10.1111/j.1346-8138.2003.tb00477.x PMID: 14684933

24. Wolfrom E, Chêne G, Lejoly-Boisseau H, Beylot C, Geniaux M, Taleb A. Chronic urticaria and Toxocara canis infection. A case-control study. Ann Dermatol Venereol 1996; 123(4):240–6. PMID: 8763746

25. Ismail MA, Khalafallah O. Toxocara canis and chronic urticaria in Egyptian patients. J Egypt Soc Parasitology 2005 Dec; 35(3):833–40. PMID: 16333893

26. González-Quintela A, Gude F, Campos J, Garea MT, Romero PA, Rey J, Meijide LM, Fernández-Merino MC, Vidal C. Toxocara infection seroprevalence and its relationship with atopic features in a general adult population. Int Arch Allergy Immunol. 2006; 139(4):317–24. https://doi.org/10.1159/000091603 PMID: 16508332

27. Kim YH, Huh S, Chung YB. Seroprevalence of Toxocariasis among healthy people with eosinophilia. Korean J Parasitol 2008; 46(1):29–32. https://doi.org/10.3347/kjp.2008.46.1.29 PMID: 18344674

28. Valenta RR, Lidholm J, Niederberg V, Hayek B, Kraft D, Gröndlund H. The recombinant allergen-based concept of component-resolved diagnostics and immunotherapy (CRD and CRIT). Clin Exp Allergy. 1999; 29:896–904. https://doi.org/10.1046/j.1365-2222.1999.00653.x PMID: 10383589

29. Brásó JV, Jorro G. Pruebas cutáneas y otras exploraciones in vivo con alérgenos. Manual de Alergia Clínica. Barcelona: Masson 2003;64–65.

30. Vidal C, Gude F, Boquete O, Fernández-Merino MC, Meijide LM, Rey J, et al. Evaluation of the Phadia-ImmunoCAP test in the diagnosis of allergic sensitization in a general adult population. Int J Invest Allergol Clin Immunol. 2005; 15:124–130.

31. Fillaux J, Magnaval JF. Laboratory diagnosis of human toxocariasis. Vet Parasitol. 2013; Apr15; 193(4):327–36. https://doi.org/10.1016/j.vetpar.2012.12.028 Epub 2012 Dec 20. PMID: 23318165

32. Rodrigo MJ, Postigo I, Wangensteen O, Guisantes JA, Martinez J. A new application of streptavidin ImmunoCAP for measuring IgG antibodies against non-available commercial antigens. Clinica Chimica Acta 2010; 411:1675–1678).

33. Ventura MT, Rodríguez-Perez R, Caballero ML, Garcia-Alonso M, Antonelli L, Asero R. IgE, IgG1 and IgG4 response to specific allergens in sensitized subjects showing different clinical reactivity to Anisakis simplex. Eur Ann Allergy Clin Immunol. 2017; 49(2):52–58. PMID: 28294584

34. Anandón AM, Romarís F, Escalante M, Rodríguez E, Gárater T, Cuéllar C, Ubeira FM. The Anisakis simplex Ani s 7 major allergen as an indicator of true Anisakis infections. Clin Exp Immunol 2009; 156 (3):471–476. https://doi.org/10.1111/j.1365-2249.2009.03919.x PMID: 19438600

35. Anadón AM, Rodríguez E, Gárater MT, Cuéllar C, Romarís F, Chivato T, Rodero M, González-Díaz H, Ubeira FM. Diagnosing human anisakiasis: recombinant Ani s 1 and Ani s 7 allergens versus the UniCAP 100 fluorescence enzyme immunoassay. Clin Vaccine Immunol 2010; 17(4):496–502. https://doi.org/10.1128/CVI.00443-09 PMID: 20107002

36. Cuéllar C, Daschner A, Valls A, De Frutos C, Fernández-Figares V, Anadón AMet al. Ani s 1 and Ani s 7 recombinant allergens are able to differentiate distinct Anisakis simplex-associated allergic clinical disorders. Arch Dermatol Res 2012; 304(4):283–8. https://doi.org/10.1007/s00403-012-1206-8 PMID: 22249742

37. Magnaval JF, Fabre R, Maurièrè P, Charlet JP, de Larrad B. Application of the Western blotting proce-dure for the immunodiagnosis of human toxocariasis. Parasitol Res 1991; 77(8):697–702. https://doi.org/10.1007/bf00928685 PMID: 1805214
38. Pawankar R, Canonica GW, Holgate ST, and Lockey RF, editors. *White Book on Allergy 2013 Update*. World Allergy Organization, 2013.

39. www.allergen.org, www.allergome.org.

40. Smith H, Holland C, Taylor M, Magnaval JF, Schantz P, Maizels R. How common is human toxocariasis? Towards standardizing our knowledge. *Trends in Parasitology* 2009; 25:182–8. https://doi.org/10.1016/j.pt.2009.01.006 PMID: 19269251

41. Minciuilio PL, Cascio A, Gangemi S. Association between urticaria and nematode infections. *Allergy Asthma Proc.* 2018 Mar 1; 39(2):86–95. https://doi.org/10.2500/aap.2018.38.4104 PMID: 29490766

42. Moreira GM, Telmo P de L, Mendonça M, Moreira AN, McBride AJ, Scaini CJ, et al. Human toxocariasis: current advances in diagnostics, treatment, and interventions. *Trends Parasitol.* 2014 Sep; 30(9):456–64. https://doi.org/10.1016/j.pt.2014.07.003 PMID: 25089038

43. Ma G, Holland CV, Wang T, Hofmann A, Fan C-K, Maizels RM, Hotez PJ, Gasser RB. Human toxocariasis. *Lancet Infect Dis* 2018; 18:e14–24. https://doi.org/10.1016/S1473-3099(17)30331-6 PMID: 28781085

44. Turrientes MC, Perez De Ayala A, Norman F, Navarro M, Perez-Molina JA, Rodriguez-Ferrer M, et al. Visceral larva migrans in immigrants from Latin America. *Emerg Infect Dis.* 2011 Jul; 17(7):1263–12659. https://doi.org/10.3201/eid1707.101204 PMID: 21762582

45. Negri EC, Santarém VA, Rubinsky-Elefant G, Giuffrida R. Anti-Toxocara spp. antibodies in an adult healthy population: serosurvey and risk factors in Southeast Brazil. *Asian Pac J Trop Biomed.* 2013 3(3):211–6. https://doi.org/10.1016/S2221-1691(13)60052-0 PMID: 23620840

46. Bolivar-Mejia A, Alarcón-Olave C, Calvo-Betancourt LS, Paniz-Mondolfi A, Delgado O, Rodríguez AJ. Toxocariasis in the Americas: Burden and Disease Control. *Curr Trop Med Rep* 2014; 1:62–68.

47. Magnaval JF, Faulingue JH, Morassin B, Fabre R. Eosinophil cationic protein, specific IgE and IgG4 in human toxocariasis. *J. Helminthol.* 2006; 80, 417–423. https://doi.org/10.1017/joh2006369 PMID: 17125552

48. Fitzsimmons CM, Falcone FH, Dunne DW. Helminth Allergens, Parasite-Specific IgE, and Its Protective Role in Human Immunity. *Front Immunol.* 2014 Feb 14; 5(61):1–12.

49. Mazzucco W, Paia DD, Marotta C, Costa A, Ferrante L, Vitale F, Casuccio A. Anisakis sensitization in different population groups and public health impact: A systematic review. *PLoS One.* 2018 20; 13(9): e0203671. https://doi.org/10.1371/journal.pone.0203671 PMID: 30235242

50. Daschner A, Pascual CY. Anisakis simplex: sensitization and clinical allergy. *Curr Opin Allergy Clin Immunol.* 2005; 5(3):281–285. https://doi.org/10.1097/01.all.0000168795.12701.fd PMID: 15864089

51. Caballero ML, Asero R, Antonelli L, Kamberi E, Colangelo C, Fazii P, de Burgos C, Rodriguez-Perez R. Anisakis allergy component-resolved diagnosis: clinical and immunologic differences between patients from Italy and Spain. *Int Arch Allergy Immunol* 2013; 162(1):39–44. https://doi.org/10.1159/000331581 PMID: 22397305

52. Fernández de Corres L, Del Pozo MD, Aizpurua F et al. Prevalencia de la sensibilización a Anisakis simplex en tres áreas españolas, en relación a las diferentes tasas de consumo de pescado. Relevancia de la alergia a Anisakis simplex. *Alergol Inmunol Clin* 2001; 16:337–346.

53. Del Pozo MD, Audicana M, Díez JM, Muñoz D, Ansótegui IJ, Fernández E, et al. Anisakis simplex, a relevant etiologic factor in acute urticaria. *Allergy* 1997; 52(5):576–579. https://doi.org/10.1111/j.1398-9995.1997.tb02603.x PMID: 9201371

54. Montoro A, Perteguer MJ, Chivot T, Laguna R, Cuéllar C. Recidivous acute urticaria caused by Anisakis simplex. *Allergy* 1997; 52(10):985–991. https://doi.org/10.1111/j.1398-9995.1997.tb02418.x PMID: 9360749

55. Lin AH, Nepstad I, Florvaag E, Egga E, Van Do T. An extended study of seroprevalence of anti-Anisakis simplex IgE antibodies in Norwegian blood donors. * scand J Immunol.* 2014 Jan; 79(1):61–7. https://doi.org/10.1111/sji.12130 PMID: 24219706

56. Caballero ML, Umpierre A, Perez-Piñar T, Moneo I, de Burgos C, Asturias JA, et al. Anisakis simplex recombinant allergens increase diagnosis specificity preserving high sensitivity. *Int Arch Allergy Immunol.* 2012; 158(3):232–40. https://doi.org/10.1159/000331581 PMID: 22398334

57. Qualizza R, Incoaraia C, Grande R, Makri E, Allegra L. Seroprevalence of IgG anti-Toxocara species antibodies in a population of patients with suspected allergy. *Int J Gen Med* 2011; 4:783–787. https://doi.org/10.2147/IJGM.S24324 PMID: 22162932

58. Frazzolini A, Cadoni S, De Pittà O. Usefulness of the CD63 basophil activation test in detecting Anisakis hypersensitivity in patients with chronic urticaria: diagnosis and follow-up. *Clin Exp Dermatol.* 2010; 35(7):765–770. https://doi.org/10.1111/j.1365-2230.2009.03694.x PMID: 19874355
59. Guillen-Bueno R, Gutiérrez-Ramos R, Perteguer-Prieto MJ, Olveira-Martín A, Fernández-Blanco I, Pouzelo-García A, et al. Anti-anisakis antibodies in the clinical course of Crohn’s disease. Digestion 1999; 60(3):268–273. https://doi.org/10.1159/000007668 PMID: 10343141

60. Yunus MH, Tan Farrizam SN, Abdul Karim IZ, Noordin R. A Lateral Flow Rapid test for human Toxocariosis developed using three Toxocara canis recombinant antigens. Antigens Am J Trop Med Hyg. 2018; 98:32–38. https://doi.org/10.4269/ajtmh.17-0632 PMID: 29141740

61. Gavignet B, Piarroux R, Aubin F, Millon L, Humbert P. Cutaneous manifestations of human toxocariasis. J Am Acad Dermatol. 2008 Dec; 59(6):1031–42. https://doi.org/10.1016/j.jaad.2008.06.031 Epub 2008 Sep 14. PMID: 18793816

62. Selekb M, Baylan O, Kulu A, Özyurt M. Toxocara Canis IgG Seropositivity in Patients with Chronic Urticaria. Iran J Allergy Asthma Immunol. August 2015; 14(4):450–456.

63. Martínez-Aranguren RM, Gamboa PM, García-Lirio E, Asturias J, Goikoetxea MJ, Sanz ML. In Vivo and In Vitro Testing With rAni s 1Can Facilitate Diagnosis of Anisakis simplex Allergy. J Investig Allergol Clin Immunol 2014; Vol. 24(6): 431–438. PMID: 25668895

64. García-Peñar JC, Rodríguez-Pérez R, Ballestero A, Zuloaga J, Fernandez-Puntero B, Arias-Díaz J, et al. Previous Exposure to the Fish Parasite Anisakis as a Potential Risk Factor for Gastric or Colon Adenocarcinoma. Medicine (Baltimore). 2015 Oct; 94(40):e1699.

65. Daschner C Cuellar M. Rodero. The Anisakis allergy debate: does an evolutionary approach help?. Trends in Parasitology January 2012; 28 (1): 9–15.

66. Lynch N.R., Wilkes L.K., Hodgen A.N., Turner K.J. Specificity of Toxocara ELISA in tropical populations. Parasite Immunol 1988; 10, 323–337. https://doi.org/10.1111/j.1365-3024.1988.tb00224.x PMID: 3412787

67. Mladineo V Poljak V Martinez-Fernandez, Ubeira F M. Anti-Anisakis IgE Seroprevalence in the Healthy Croatian Coastal Population and Associated Risk Factors. PLoS Negl Trop Dis. 2014; 8(2):e2673. https://doi.org/10.1371/journal.pntd.0002673 PMID: 24516680

68. Johansson E, Aponno M, Lundberg M, Hage-Hamsten M. Allergic cross-reactivity between the nematodes Anisakis simplex and the dust mites Acarus siro, Lepidoglyphus destructor, Tyrophagus putrescentiae, and Dermatophagoides pteronyssinus. Allergy 2001; 56:660–666. https://doi.org/10.1034/j.1398-9995.2001.00798.x PMID: 11421925

69. Lozano M, Martín HL, Díaz SV, Mañas AI, Valero LA, Campos BM. Cross-reactivity between antigens of Anisakis simplex and other ascarid nematodes. Parasite 2004; 11:219–223. https://doi.org/10.1051/parasite/2004112219 PMID: 15224584

70. Puente P, Anadón AM, Rodero M, Romaris F, Ubeira FM, Cuelián C. Anisakis simplex: the high prevalence in Madrid (Spain) and its relation with fish consumption. Exp. Parasitol. 2008; 118: 271–274. https://doi.org/10.1016/j.exppara.2007.07.002 PMID: 17825294

71. Treudler R, Simon JC. Overview of component resolved diagnostics. Curr Allergy Asthma Rep. 2013; 13(1):110–117. https://doi.org/10.1007/s11882-012-0318-8 PMID: 23076421

72. Matricardi PM, Kleine-Tebbe J, Hoffmann HJ, Valenta R et al. EAACI Molecular Allergology User’s Guide. Pediatric Allergy and Immunology 2016: 27: (suppl 23): 1–250

73. Zhan B, Ajmera R, Geiger SM, Gonçalves MT et al. Identification of immunodominant antigens for the laboratory diagnosis of toxocariasis Trop Med Int Health. 2015; 20(12):1787–1796. https://doi.org/10.1111/tmi.12607 PMID: 26426162

74. Olave AM, Mesa JA, Botero JH, Patiño EB, García GM, Alzate JF. Producción y evaluación del antígeno recombinante TES-30 de Toxocara canis para el inmunodiagnóstico de toxocariasis. Biomédica 2016; 36:39–51. https://doi.org/10.7705/biomedica.v36i1.2617 PMID: 27622437

75. Yamasaki H, Arai K, Lim PK, Zasmy N, Mak JW, Taib Ret al. Development of a highly specific recombinant Toxocara canis second-stage larva excretory-secretory antigen for immunodiagnosis of human toxocariasis. J Clin Microbiol. 2000; 38:1409–13. PMID: 10747116

76. Nwaru BI, Hickstein L, Panesar SS, Roberts G, Muraro A and Sheikh A on behalf of the EAACI Food Allergy and Anaphylaxis Guidelines Group. Prevalence of common food allergies in Europe: a systematic review and meta-analysis. Allergy 2014; 69: 992–1007. https://doi.org/10.1111/all.12423 PMID: 24816523